PHARMACYTE BIOTECH, INC. (PMCB) Total liabilities 2017–2026
PHARMACYTE BIOTECH, INC. (PMCB) total liabilities at each fiscal year-end, per SEC filings.
$11.8MFY2026 · since FY2017: $580,248 → $11.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $11.8M | +259.2% |
| FY2025 | $3.3M | -83.9% |
| FY2024 | $20.4M | +3376.0% |
| FY2023 | $586,581 | -16.7% |
| FY2022 | $704,370 | -2.8% |
| FY2021 | $724,778 | -32.7% |
| FY2020 | $1.1M | +45.1% |
| FY2019 | $742,851 | +15.3% |
| FY2018 | $644,168 | +11.0% |
| FY2017 | $580,248 | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More PMCB financial trends
PMCB RevenuePMCB Net incomePMCB Net marginPMCB Gross profitPMCB Gross marginPMCB Operating incomePMCB Operating marginPMCB Operating cash flowPMCB Free cash flowPMCB Capital expendituresPMCB Return on equityPMCB Stock buybacksPMCB Dividends paidPMCB Total assetsPMCB Shareholders’ equityPMCB overview →